E Welkowsky

Learn More
BACKGROUND We analyzed the potential of abiraterone acetate (henceforth abiraterone) to reduce androgen levels below lower limits of quantification (LLOQ) and explored the association with changes in PSA decline in metastatic castration-resistant prostate cancer (mCRPC) patients. METHODS COU-AA-301 is a 2:1 randomized, double-blind, placebo-controlled(More)
  • 1